GlobeNewswire by notified

Low/no calorie sweeteners do not increase the risk of cardiovascular diseases

Share

ISA statement in response to new study by Debras, Chazelas et al.

BRUSSELS, Belgium, Sept. 08, 2022 (GLOBE NEWSWIRE) -- The International Sweeteners Association (ISA) responds to the new study by Debras, Chazelas et al.1 on low/no calorie sweeteners and cardiovascular diseases highlighting that, contrary to claims made in this study, there is no causal evidence that low/no calorie sweeteners could increase the risk of cardiovascular diseases (CVDs).

Indeed, whilst the Debras, Chazelas et al study claim to show an association between low/no calorie sweeteners intake and CVD risk, there is no evidence of a plausible mechanism to support potential effects of low/no calorie sweeteners on cardiometabolic health.2The safety of all approved low/no calorie sweeteners has been confirmed by food safety bodies worldwide including the Joint Expert Committee on Food Additives of the United Nations Food and Agriculture Organization (FAO) and of the World Health Organization (WHO)3, the European Food Safety Authority (EFSA)4, and the US Food and Drug Administration (FDA)5.

Actually, the intake of low/no calorie sweeteners in the NutriNet-Santé cohort was extremely low, even for higher consumers (defined in the study as participants with sweetener intake above the sex specific median among consumers). Importantly, experts have questioned the ability to detect an association between low/no calorie sweeteners at such low levels of intake and any health outcome and stressed that, in such circumstances, confounding factors become more influential.6 By design, observational studies cannot establish a cause-and-effect relationship due to their observational nature and the inability to exclude residual confounding or, importantly, attenuate the effects of reverse causality.7

Contrary to the study by Debras, Chazelas et al, a systematic review and meta-analysis of prospective cohort studies including change and substitutions analyses that mitigate the influence of reverse causality providing more consistent and robust associations found that low/no calorie sweetened beverages are associated with lower risk of coronary heart disease and CVD mortality in the intended substitution for sugar-sweetened beverages.8 These findings are in line with evidence from randomised controlled trials which confirm no adverse effect of low/no calorie sweeteners on cardiometabolic risk factors including blood pressure, lipid levels, blood glucose and body weight, and in fact some benefits when used to replace sugars in the diet. 9,10

At a time when non-communicable diseases including diabetes and dental diseases remain major global health challenges, and in light of current public health recommendations to reduce overall sugar intake, low/no calorie sweeteners can be helpful in creating healthier food environments. They provide people with a wide choice of sweet-tasting options with low or no calories, and thus can be a useful tool, when used in place of sugar and as part of a balanced diet, in helping reduce overall sugar and calorie intake, as well as in managing blood glucose levels.11 Low/no calorie sweeteners are also not fermentable by oral bacteria, which means that they do not contribute to tooth demineralisation, which is one of the reasons for tooth decay.12

1 Debras C, Chazelas E, Sellem L, et al. Artificial sweeteners and risk of cardiovascular diseases: results from the prospective NutriNet-Santé cohort. BMJ 2022;378:e071204.
2 Pyrogianni V, La Vecchia C. Letter by Pyrogianni and La Vecchia Regarding Article, “Artificially Sweetened Beverages and Stroke, Coronary Heart Disease, and All-Cause Mortality in the Women’s Health Initiative”. Stroke. 2019 Jun;50(6):e169
3http://www.fao.org/food/food-safety-quality/scientific-advice/jecfa/en/
4http://www.efsa.europa.eu/en/topics/topic/sweeteners
5https://www.fda.gov/food/food-additives-petitions/high-intensity-sweeteners
6 Magnuson B. Comments in response to the article by Debras et al “Artificial sweeteners and cancer risk: Results from the NutriNet-Santé population-based cohort study”. Available at: https://journals.plos.org/plosmedicine/article/comment?id=10.1371/annotation/edab6e54-e06a-4e33-ba10-f1a96bc43152
7 La Vecchia C. Comments in response to the article by Debras et al “Artificial sweeteners and cancer risk: Results from the NutriNet-Santé population-based cohort study”. Available at: https://journals.plos.org/plosmedicine/article/comment?id=10.1371/annotation/e28d577e-cd1c-42eb-85aa-7ea0cf0d5ccd
8 Lee JJ, Khan TA, McGlynn et al. Relation of Change or Substitution of Low- and No-Calorie Sweetened Beverages With Cardiometabolic Outcomes: A Systematic Review and Meta-analysis of Prospective Cohort Studies. Diabetes Care. 2022 Aug 1;45(8):1917-1930
9 McGlynn ND, Khan TA, Wang L, et al. Association of Low- and No-Calorie Sweetened Beverages as a Replacement for Sugar-Sweetened Beverages With Body Weight and Cardiometabolic Risk: A Systematic Review and Meta-analysis. JAMA Network Open 2022 Mar 1;5(3):e222092
10 Rios-Leyvraz M, Montez J (World Health Organization)‎. Health effects of the use of non-sugar sweeteners: a systematic review and meta-analysis. World Health Organization (WHO) 2022. https://apps.who.int/iris/handle/10665/353064. License: CC BY-NC-SA 3.0 IGO
11 Diabetes UK. The use of low or no calorie sweeteners. Position Statement (Updated December 2018). Available at: https://www.diabetes.org.uk/professionals/position-statements-reports/food-nutrition-lifestyle/use-of-low-or-no-calorie-sweetners
12 EFSA Scientific opinion on the substantiation of health claims related to intense sweeteners. EFSA 2011 Journal 9(6): 2229, and 9(4): 2076

ISA - Avenue de Tervueren 13A – Bte 7, B-1040 Brussels, Belgium - Tel: +32 (0)2 736 53 54 - Fax: +32 (0)2 732 34 27
E-mail: info@sweeteners.org - Website: www.sweeteners.org - TVA BE 424.301.259

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Neurosurgery Customer from Germany Orders Nexstim NBS System 526.4.2024 14:00:00 CEST | Press release

Press release, Helsinki, 26 April 2024 at 3 PM (EEST) Neurosurgery Customer from Germany Orders Nexstim NBS System 5 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for a new NBS System 5 from an existing customer hospital in Germany. The system will be used in neurosurgery. The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus and localization of cortical areas that do not contain essential speech function. The information gained from the mapping may be used in pre-procedural planning. Mikko Karvinen, CEO of Nexstim, comments: “Our diagnostics system offers a unique possibility for neurosurgeons to receive crucial information about the location of vital functional areas before a surgery. We are happy to have one of our existing customers in Germany order a new NBS 5 system. This is a clear sign of the commitment that the Nexstim team has in maintaining long-term

Benevity’s 2024 Corporate Goodness Awards Celebrate Groundbreakers in Social Impact26.4.2024 13:00:00 CEST | Press release

Awards recognize purpose-driven brands for their extraordinary approaches to social impact, corporate philanthropy and employee engagement PALM SPRINGS, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Benevity Inc., the leading global provider of social impact software, today announced the winners of its 2024 Corporate Goodness Awards, also known as “The Goodies,” acknowledging leading-edge brands for their innovative and inspirational approaches to social impact, employee engagement and corporate philanthropy. The 2024 Goodie Awards were presented to the winners on April 25 in Palm Springs, CA at Benevity Live!, the company’s flagship conference, which brings together more than 700 purpose-driven professionals to share insights and strategies about the future of corporate impact. This year saw a record-breaking 197 nominations from 99 of the world’s most iconic and purpose-driven brands. The winners were recognized across various categories based on the innovative, inclusive and creative w

NGS Group AB: Offentliggör årsredovisning 202326.4.2024 13:00:00 CEST | Pressemelding

Härmed offentliggör NGS Group AB (publ) sin årsredovisning för 2023. Årsredovisningen finns även tillgänglig på bolagets hemsida www.ngsgroup.se. För ytterligare information kontakta: Thomas Plate, CFO för NGS Group på telefon 076-894 9239 eller mailadress thomas.plate@ngsgroup.se. Denna information är sådan som NGS Group AB (publ) är skyldig att offentliggöra enligt lagen om värdepappersmarknaden, lagen om handel med finansiella instrument samt Nasdaq Stockholms regelverk. Informationen lämnades för offentliggörande den 26 april 2024. Bilagor Årsredovisning 2023 - NGS Group AB (publ)ngsgroupab-2023-12-31-sv

Digitalist Group Plc - Managers' Transactions26.4.2024 13:00:00 CEST | Press release

Digitalist Group Plc Managers’ transactions 26 April 2024 at 14:00 Digitalist Group Plc - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Turret Oy Ab Position: Closely associated person (X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer Name: Paul Ehrnrooth Position: Member of the Board (2):Person Discharging Managerial Responsibilities In Issuer Name: Peter Eriksson Position: Member of the Board Issuer: Digitalist Group Oyj LEI: 743700AL68PUX6JMS644 Notification type: INITIAL NOTIFICATION Reference number: 59985/5/6 ____________________________________________ Transaction date: 2024-04-26 Venue: OFF-EXCHANGE LIIKETOIMET (XOFF) Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT Name of the instrument: igitalist Group Oyj:n Vaihtovelkakirjalaina 2021/1 Nature of transaction: SUBSCRIPTION Transaction details (1): Volume: 65000000 Unit price: 0 N/A Aggregated tran

Forløb af ordinær generalforsamling i ØK - Selskabsmeddelelse nr. 4/202426.4.2024 12:57:02 CEST | pressemeddelelse

26. april 2024 Den 26. april 2024 kl. 11.00 afholdtes ordinær generalforsamling i Det Østasiatiske kompagni A/S, i Asia House, Indiakaj 16, 2100 København Ø. På den ordinære generalforsamling blev følgende dagsordenspunkter behandlet: a. Bestyrelsens beretning blev taget til efterretning. b. Årsrapporten for 2023 blev godkendt. c. Der blev meddelt decharge for bestyrelsen og direktionen. d. Anvendelse af årets resultat i overensstemmelse med den godkendte årsrapport blev godkendt. e. Præsentation af vederlagsrapporten for 2023. f. Bestyrelsens honorar for 2024 blev vedtaget. g. Ole Steffensen, Martin Thaysen og Kresten M. Valdal blev valgt som medlemmer til bestyrelsen. h. KPMG P/S blev genvalgt som selskabets revisor. i. Bestyrelsen bemyndigedes til at lade selskabet erhverve egne aktier. j. Forslag fra bestyrelsen om: Selskabets vederlagspolitik blev godkendt.Forslaget om ændring af selskabets navn til ”Det Østasiatiske Kompagni A/S” og optagelse af binavne blev vedtaget. k. Dirigent

HiddenA line styled icon from Orion Icon Library.Eye